Insulin costs have declined over the past two years, and additional price cuts are expected in 2026. Medicare will lower prices for several diabetes drugs, including Januvia and Jardiance. Federal and ...

Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and ...

Eli Lilly (NYSE: LLY) shares rose 6% in the premarket on Thursday after the drugmaker beat Wall Street expectations with its ...

Eli Lilly’s fair value estimate has recently been raised from $891.62 to $919.33. This reflects a modest increase in the company’s intrinsic valuation amid evolving market sentiment. The upward ...

The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

The expansion of Lilly del Caribe facility in Carolina, Puerto Rico will add 100 new jobs.

The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...

Eli Lilly LLY has been on an acquisition spree since the beginning of this year to bolster its pipeline, which should drive ...